文献速递垂体与肾上腺疾病

KCNJ5依赖的68Ga-Pentixafor PET/CT在原醛症手术中的应用

KCNJ5-Dependent 68Ga-Pentixafor PET/CT in Primary Aldosteronism Surgery.
PubMed 文献 · J Clin Endocrinol Metab · 2026-07-30

该单中心回顾性队列纳入162例接受单侧肾上腺切除的原醛症患者,比较PET/CT引导与AVS引导路径的术后结局。PET/CT单侧阳性对AVS单侧确诊的阳性预测值高(56/57,98.2%),但26/82例AVS确诊单侧患者PET为阴性或双侧。所有KCNJ5突变患者PET均阳性,52例非突变者中22例PET阴性。

要点

  • PET/CT单侧明显摄取时对单侧原醛症有很强确诊价值。
  • PET阴性或双侧摄取尤其在小病灶或KCNJ5非突变者中不能排除AVS评估。
  • KCNJ5突变和CT病灶大小与PET阳性独立相关。

核心结论

  • 68Ga-pentixafor PET/CT在摄取明确单侧时提供强确诊信息,但阴性或双侧结果应谨慎解读,不应排除AVS评估。

研究设计与样本

  • 回顾性单中心队列筛选929例疑似原醛症患者,最终纳入162例接受单侧肾上腺切除并随访6个月,其中83例同时行AVS。
  • 2024年9月前治疗者遵循AVS引导路径,此后治疗者遵循PET/CT引导路径,结局按PASO标准评估。

主要发现

  • PET引导组与AVS引导组的临床和生化完全成功无显著差异。
  • 同时接受两项检查的患者中,PET/CT单侧阳性对AVS单侧确诊的阳性预测值为56/57(98.2%)。
  • 82例AVS确诊单侧原醛症中26例PET阴性或双侧。
  • PET状态队列中所有KCNJ5突变患者PET均为阳性,52例KCNJ5非突变患者中22例PET阴性。
  • KCNJ5突变和CT病灶大小与PET阳性独立相关,SUVmax LI与生化完全成功相关(包括KCNJ5非突变患者)。

关键数值与推荐

  • PET/CT单侧阳性对AVS单侧确诊的阳性预测值为56/57(98.2%)。
  • 82例AVS确诊单侧患者中26例PET阴性或双侧。
  • 52例KCNJ5非突变患者中22例PET阴性。

临床怎么用

  • PET/CT显示明确单侧摄取时可支持直接手术决策。
  • PET/CT阴性或双侧摄取时应行AVS评估,尤其在小病灶或KCNJ5非突变患者中。

局限性

  • 回顾性单中心设计。
  • PET/CT引导与AVS引导路径按治疗时间划分,非随机对照。
  • 仅83例同时接受AVS和PET/CT检查,配对分析样本有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate 68Ga-pentixafor PET/CT in the surgical management of primary aldosteronism (PA), with emphasis on its relationship with adrenal venous sampling (AVS), KCNJ5 mutation status, tracer uptake, and postoperative outcomes. PATIENTS AND METHODS: This retrospective single-center cohort screened 929 consecutive patients with suspected PA from November 2021 to February 2025. The final cohort included 162 patients who underwent unilateral adrenalectomy and 6-month follow-up; 83 also underwent AVS. Patients treated before September 2024 followed an AVS-guided pathway, and those treated thereafter followed a PET/CT-guided pathway. Outcomes were assessed by PASO criteria. Firth logistic regression, overlap weighting, paired PET/CT-versus-AVS analysis, and genotype-stratified analyses were performed. RESULTS: Clinical and biochemical complete success did not differ significantly between the PET-guided and AVS-guided groups. Among patients with both tests, unilateral PET/CT showed high positive predictive value versus AVS (56/57, 98.2%), but 26 of 82 AVS-confirmed unilateral PA cases had negative or bilateral PET findings. All KCNJ5-mutated patients in the PET-status cohort were PET-positive, whereas 22 of 52 KCNJ5-nonmutated patients were PET-negative. KCNJ5 mutation and CT lesion size were independently associated with PET positivity. SUVmax LI was associated with biochemical complete success, including within KCNJ5-nonmutated patients. CONCLUSIONS: 68Ga-pentixafor PET/CT provides strong rule-in information when uptake is clearly unilateral. Negative or bilateral PET/CT, especially in small or KCNJ5-nonmutated lesions, should be interpreted cautiously and should not preclude AVS-based evaluation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang Z, Luo J, Guan L, et al. KCNJ5-Dependent 68Ga-Pentixafor PET/CT in Primary Aldosteronism Surgery. J Clin Endocrinol Metab. 2026. PMID: 42531454. doi:10.1210/clinem/dgag301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。